Market Overview:
The global oral hypoglycemic drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising awareness about oral hypoglycemic drugs, and technological advancements in the field of oral hypoglycemic drugs. Based on type, the global oral hypoglycemic drugs market is segmented into sulfonylureas (SU), double guanidine, glucosidase inhibitors, and insulin synergists. The sulfonylureas segment is expected to account for the largest share of the global oral hypoglycemic drugs market in 2018.
Product Definition:
Oral hypoglycemic drugs are medications that help to control blood sugar levels in people with diabetes. They work by causing the pancreas to release more insulin, or by preventing the absorption of glucose from the intestines. Oral hypoglycemic drugs are important for controlling blood sugar levels and preventing diabetes-related complications.
Sulfonylureas (SU):
Sulfonylureas are hypoglycemic drugs that stimulate the release of insulin from the pancreas. They cause an increase in the urine sugar level and decrease in blood sugar levels. Sulfonylurea was discovered by accident when a research worker noticed that his co-workers who had sweeter than normal personalities also happened to be less susceptible to diabetes mellitus.
Double Guanidine:
Double guanidine is an oral hypoglycemic drug which helps in increasing the duration and improving the quality of life of patients suffering from diabetes. It works by decreasing glucose levels in the body, thereby reducing or eliminating symptoms such as shakiness, sweating, and anxiety which usually occur when a patient is unable to get sugar into his/her system.
Application Insights:
Based on the application, the global oral hypoglycemic drugs market is segmented into hospital, clinic and others. The hospital segment dominated the overall market in terms of revenue in 2017. This can be attributed to a high prevalence of diabetes and increasing awareness about early diagnosis and treatment of this disease. According to WHO, approximately 463 million people have diabetes worldwide out of which around 142 million are diagnosed every year. In addition, according to data published by International Diabetes Federation (IDF), currently around 870 million adults are suffering from prediabetes symptoms where over 250 thousand die due to cardiovascular diseases annually if not treated or managed properly leading to an increase in demand for OHDs globally as well as locally during past few years especially during 2014-2016 period when compared with previous years owingto increased usage among patients suffering from prediabetes or at risk of developing type 2 diabetes soon which is expectedto boost product demand over forecast period significantly.
Regional Analysis:
Asia Pacific is expected to be the fastest growing region over the forecast period owing to rising incidences of type I and type II diabetes. Moreover, increasing healthcare expenditure in emerging economies such as India and China are anticipated to fuel market growth during the forecast period. In addition, growing awareness about oral hypoglycemic drugs in this region will drive demand for OHDs in Asia Pacific.
In 2016, Japan was one of the largest markets for OHDs with a revenue share of around 13%. The presence of advanced manufacturing facilities coupled with high R&D investment by global players is likely to contribute towards market growth during the projected time frame. Furthermore, favorable reimbursement policies pertaining to new drug development are also expected favorably impact overall regional market dynamics over the next eight years.
Europe accounted for approximately 27% share in 2016 owing to its well-established pharmaceutical industry coupled with highly developed healthcare infrastructure offering world-class services across major countries including Germany, France.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is primarily due to the changing lifestyle and dietary habits of people across the world. As a result, there is an increased demand for oral hypoglycemic drugs to manage blood sugar levels in diabetic patients.
- Technological advancements in oral hypoglycemic drugs: Pharmaceutical companies are constantly investing in research and development to come up with newer and more effective oral hypoglycemic drugs. This has led to the introduction of several novel drug formulations in the market that are more efficacious and better tolerated by patients than older products.
- Growing awareness about diabetes management: There is a growing awareness among people about the importance of early diagnosis and proper management of diabetes mellitus for preventing its long-term complications. This has led to an increase in demand for oral hypoglycemic drugs, especially those that offer convenience and flexibility of use like tablets or capsules instead injections or pens .
Scope Of The Report
Report Attributes
Report Details
Report Title
Oral Hypoglycemic Drugs Market Research Report
By Type
Sulfonylureas (SU), Double Guanidine, Glucosidase Inhibitor, Insulin Synergist
By Application
Hospital, Clinic, Others
By Companies
Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Merck & Co, Eli Lilly, Sanofi, Takeda Pharmaceuticals, Novo Nordisk, Servier Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
164
Number of Tables & Figures
115
Customization Available
Yes, the report can be customized as per your need.
Global Oral Hypoglycemic Drugs Market Report Segments:
The global Oral Hypoglycemic Drugs market is segmented on the basis of:
Types
Sulfonylureas (SU), Double Guanidine, Glucosidase Inhibitor, Insulin Synergist
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- AstraZeneca
- Johnson & Johnson
- GlaxoSmithKline
- Merck & Co
- Eli Lilly
- Sanofi
- Takeda Pharmaceuticals
- Novo Nordisk
- Servier Laboratories
- Boehringer Ingelheim
- Bristol-Myers Squibb
Highlights of The Oral Hypoglycemic Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Sulfonylureas (SU)
- Double Guanidine
- Glucosidase Inhibitor
- Insulin Synergist
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oral Hypoglycemic Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oral hypoglycemic drugs (OHPs) are medications that help to lower blood sugar levels. They are often prescribed to people with diabetes who have difficulty controlling their blood sugar levels on their own. OHP medications work by decreasing the amount of glucose in the bloodstream.
Some of the major players in the oral hypoglycemic drugs market are Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Merck & Co, Eli Lilly, Sanofi, Takeda Pharmaceuticals, Novo Nordisk, Servier Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb.
The oral hypoglycemic drugs market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oral Hypoglycemic Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oral Hypoglycemic Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oral Hypoglycemic Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oral Hypoglycemic Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oral Hypoglycemic Drugs Market Size & Forecast, 2020-2028
4.5.1 Oral Hypoglycemic Drugs Market Size and Y-o-Y Growth
4.5.2 Oral Hypoglycemic Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Sulfonylureas (SU)
5.2.2 Double Guanidine
5.2.3 Glucosidase Inhibitor
5.2.4 Insulin Synergist
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oral Hypoglycemic Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oral Hypoglycemic Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Sulfonylureas (SU)
9.6.2 Double Guanidine
9.6.3 Glucosidase Inhibitor
9.6.4 Insulin Synergist
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Sulfonylureas (SU)
10.6.2 Double Guanidine
10.6.3 Glucosidase Inhibitor
10.6.4 Insulin Synergist
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Sulfonylureas (SU)
11.6.2 Double Guanidine
11.6.3 Glucosidase Inhibitor
11.6.4 Insulin Synergist
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Sulfonylureas (SU)
12.6.2 Double Guanidine
12.6.3 Glucosidase Inhibitor
12.6.4 Insulin Synergist
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Sulfonylureas (SU)
13.6.2 Double Guanidine
13.6.3 Glucosidase Inhibitor
13.6.4 Insulin Synergist
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oral Hypoglycemic Drugs Market: Competitive Dashboard
14.2 Global Oral Hypoglycemic Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 AstraZeneca
14.3.3 Johnson & Johnson
14.3.4 GlaxoSmithKline
14.3.5 Merck & Co
14.3.6 Eli Lilly
14.3.7 Sanofi
14.3.8 Takeda Pharmaceuticals
14.3.9 Novo Nordisk
14.3.10 Servier Laboratories
14.3.11 Boehringer Ingelheim
14.3.12 Bristol-Myers Squibb
